Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

---

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 26, 2025

---

(Exact name of registrant as specified in its charter)

---

---

---

Registrant’s telephone number, including area code: (646) 440-9100

---

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

On April 26, 2025, R. Keith Woods informed the board of directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company”) that he has accepted a Chief Operating Officer position with a biopharmaceutical company and therefore has decided not to stand for re-election to the Board at the Company’s upcoming 2025 annual meeting (the “2025 Annual Meeting”). As a result, Mr. Woods’ term as a director, including his membership on the Board’s audit committee and commercial committee, will end at the 2025 Annual Meeting.

The decision by Mr. Woods to not stand for re-election to the Board at the 2025 Annual Meeting did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---